REVIEW

Recent advances in understanding/managing eosinophilic esophagitis in adults [version 1; peer review: 2 approved, 1 approved with reservations]

David A. Katzka

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

V1 First published: 20 Aug 2015, 4(F1000 Faculty Rev):592
<https://doi.org/10.12688/f1000research.6942.1>

Latest published: 20 Aug 2015, 4(F1000 Faculty Rev):592
<https://doi.org/10.12688/f1000research.6942.1>

Abstract

It is an exciting time for research in eosinophilic esophagitis (EoE). As a new and increasingly prevalent disease, it is receiving considerable attention in the medical world, resulting in a flood of new insights. Clearly, a genetic predisposition seems likely with the identification of abnormalities in thymic stromal lymphopoietin (TSLP), calpain14, and eotaxin-3 genes. There are also well-defined abnormalities described in esophageal epithelial barrier function in these patients. The relationship between gastroesophageal reflux disease (GERD) and EoE remains unclear, but emerging data suggest that the concept of proton pump inhibitor responsive esophageal eosinophilia (PIREE) may retain less importance, as this subset of patients becomes a likely subset of EoE in general. Finally, we approach the looming issue of long-term maintenance therapy. Although we lack adequate specific data on how to provide long-term pharmacologic treatment, studies clearly show that for most patients, this is a progressive disease that warrants such consideration.

Keywords

eosinophilic, esophagitis

Open Peer Review

Approval Status

	1	2	3
version 1
20 Aug 2015			
1. Chris Liacouras , The Children's Hospital of Philadelphia, Philadelphia, UK			
2. Marc Rothenberg , Cincinnati Children's Hospital Medical Center, Cincinnati OH, USA			
3. Jonathan Markowitz , Greenville Hospital System University Medical Center, Greenville, USA			
Any comments on the article can be found at the end of the article.			

Corresponding author: David A. Katzka (katzka.david@mayo.edu)

Competing interests: The author declares that he has no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2015 Katzka DA. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Katzka DA. **Recent advances in understanding/managing eosinophilic esophagitis in adults [version 1; peer review: 2 approved, 1 approved with reservations]** F1000Research 2015, 4(F1000 Faculty Rev):592
<https://doi.org/10.12688/f1000research.6942.1>

First published: 20 Aug 2015, 4(F1000 Faculty Rev):592 <https://doi.org/10.12688/f1000research.6942.1>

Introduction

It is not often in medicine that we have the excitement of researching and understanding a new disease, but this has occurred with eosinophilic esophagitis (EoE). Neither described nor understood until the 1990s, a wealth of information on EoE has emerged over the past two decades. It is remarkable that within such a relatively short period of time, major advances in understanding its molecular and clinical pathogenesis, disease characteristics, and treatment options have been defined. Nevertheless, a need for greater understanding of this disease, including basic questions with regard to diagnosis and treatment, remains. The goal of this review is to present many of the known highlights of EoE with identification of the key questions that need to be answered in the future.

Pathophysiology

EoE appears to fall within the paradigm of an allergic disease with a genetic predisposition. In children, several genetic abnormalities have been identified, including in the eotaxin-3 gene and thymic stromal lymphopoietin (TSLP)^{1–5}. More than just association, these abnormalities may have clear functional consequences. For example, the eotaxin-3 gene codes for eotaxin, which is a strong chemoattractant for eosinophils⁶. TSLP, on the other hand, is a key promotor of T(H)2 responses found in EoE³. There are also reported abnormalities in the epidermal differentiation complex (EDC) genes that code for filaggrin, an important protein regulator of the epithelial barrier⁷ and the calpain 14 gene⁸. These data are not surprising, as allergic disorders, such as asthma, atopic dermatitis, and seasonal allergies, commonly affect multiple family members and are thought to also have a genetic predisposition.

The proof that EoE is an allergy-based disease comes from several types of data. The first is in animal models in which EoE has been recapitulated in a mouse model⁹. Interestingly, there appears to be a “two-hit” pathway in which animal priming with first airway disease (by administration of intratracheal *Aspergillus*) or skin disease (by subcutaneous injection with ovalbumin) is needed to induce esophageal eosinophilia¹⁰. With this model, a careful analysis of the Th2 allergy pathway found in EoE has revealed multiple levels of involvement including an initial exposure of food antigens to dendritic cell recognition in the esophageal epithelium, epithelial secretion of key cytokines and eosinophil attractants, and recruitment of eosinophils and mast cells leading to esophageal inflammation and fibrosis^{11,12}. Data in adults that corroborate these hypotheses include confirmation of the Th2 reaction histologically, identification of elevation of similar cytokines including eotaxin, and the frequent presence of extraesophageal allergies in patients^{13–15}. This last point includes the finding that airway allergies commonly precede the onset of EoE. Some of the most compelling data suggesting that EoE is an allergy-based disease come from response to therapy. Specifically, medications such as steroids, which are useful in allergic diseases, are effective in inducing histologic remission in EoE^{16–18}. Moreover, removal of food antigens by using an elemental diet (i.e. a diet devoid of food antigens) leads to histologic remission in close to 100% of EoE patients^{19–22}.

Other important mechanisms have also been postulated as being contributory to EoE. One area of investigation includes how food

antigens putatively gain access to the esophageal epithelium. Towards this end, investigators have demonstrated that patients with EoE have altered esophageal epithelial permeability, as shown through Ussing chambers containing biopsies and by an endoscopically placed mucosal impedance probe²³. Histologically, the epithelium in EoE demonstrates the presence of dilated intercellular spaces consistent with these physiologic findings. Furthermore, abnormalities in tight junction proteins, an important regulator of intercellular space diameter, have been shown in EoE tissue, some of which may become normal with the use of steroids⁶. Thus, a clear pathway of how antigen penetration into esophageal epithelium, with subsequent recognition by the dendritic cell, is evolving.

In adults, an extremely important aspect of pathophysiology that is being explored is the mechanism of fibrosis in the esophageal wall with subsequent ring and stricture formation that commonly accompanies EoE. Investigators have clearly shown that in EoE, there is a secretion of fibrogenic peptides with esophageal remodeling²⁴ that may improve with steroids²⁵. The potential for this fibrosis is presumably related to ongoing uncontrolled esophageal inflammation. Furthermore, a recent fascinating study shows that IgG4, a known immunoglobulin associated with fibrosis in other diseases²⁶, may also be important in EoE.

Finally, there are compelling data that EoE is a genetic disease. Demographic data show that a personal and family history of allergies is common in patients with EoE¹⁴. It has also been described in first-degree relatives both vertically and horizontally^{27,28}. As previously noted, two genetic abnormalities have been identified in up to 50% of children.

Diagnosis

As in an early description of any new disease, a classic set of characteristics emerges. In EoE, it became readily apparent that these characteristics include its occurrence in white male children and young adults, a presentation with dysphagia, and an endoscopic appearance of rings, furrows, white exudates and strictures associated with esophageal eosinophilia^{29–32}. As recognition of EoE has evolved, it has become clear that these characteristics are not entirely specific, particularly in patients with gastroesophageal reflux disease (GERD)³³. Indeed, the greatest diagnostic challenge in EoE is distinguishing it from GERD. This task is formidable for several reasons. Firstly, as discussed, clinical features overlap. Secondly, GERD is a common disease and may co-exist with EoE. Thirdly, recent data suggest that GERD may potentiate EoE but cause the initial dilation of intercellular spaces and the subsequent increase in esophageal permeability²³. Fourthly, the results of ambulatory pH monitoring do not lead to accurate differentiation of these two diseases in all patients³⁴. Fifthly, histologically there are no obvious routine histologic markers nor special stains (e.g. of mast or eosinophil-derived proteins) that distinguish these two diseases^{35,36}. Finally, proton pump inhibitors (PPIs) are therapeutic not only in GERD but also in EoE, where they may have cytokine-blocking effects independent of the acid-suppressing mechanism^{37,38}. As a result, this has led to a newly defined category of patients, labeled PPI-responsive esophageal eosinophilia (PPIREE). Whether this truly represents a different phenotype of disease or a combination

of EoE and GERD is unclear, although preliminary data suggest that PPIREE patients may eventually progress to EoE. It is the author's opinion that categorization should be based on the terms EoE, GERD, and an overlap of the two³⁹.

Just as the typical characteristics of EoE are not diagnostic, we are starting to observe patients with atypical features of EoE. For example, whereas it was assumed that all adults with EoE have dysphagia, some patients are now being seen with heartburn or nausea as their presenting symptom⁴⁰. This is common in children where the isolated inflammatory response might be expected to produce such symptoms but was not expected in adults⁴⁰. Similarly, approximately 5% of adult patients will have a normal endoscopic appearance. These data must be considered carefully, however, as endoscopy is relatively insensitive to the detection of esophageal strictures when compared to barium esophagography¹⁸. Thus, a normal endoscopic appearance may not reflect a truly normal esophagus.

With the lack of a gold standard for the diagnosis of EoE, establishing the diagnosis at this point still necessitates a combination of compatible clinical, endoscopic (and perhaps, radiologic), and histologic criteria, as recently defined³⁰. Needless to say, this definition will continue to evolve.

Treatment

Before discussing specific treatment options, it is important to understand some of the fundamental questions on treatment that have not been answered. The most essential question is what is the desired endpoint of treatment? The present options are symptoms, histology or both. Although symptom resolution is a desirable endpoint of any therapy, it is problematic in EoE where symptom resolution correlates poorly to other important endpoints, such as histology¹⁸. This is not surprising in adults, as short-term eradication of the esophageal epithelial inflammatory response does not lead to improvement of the fibrotic strictures that typically generate the symptoms of dysphagia. Another confounding issue in assessing symptoms is the lack of a standardized and comprehensive means of accurately measuring response. A study in press from the Swiss Eosinophilic Esophagitis Group will contribute greatly to resolving this problem, but, at this point, many physicians do not appreciate the subtle and adaptive behaviors that EoE patients adopt to cope with their disease and which can lead to inaccurate assessment of symptoms⁴¹. The third issue is in the way we define treatment groups. For the past 5 years, patients with esophageal eosinophilia who respond to PPIs are termed as either GERD patients or PPI-responsive eosinophilia. As data continue to accumulate in this area, particularly histologic and cytokine data, it appears that those patients with PPIREE, that is patients with the phenotype of EoE who do respond to PPIs, are likely a subset of EoE and will be referred to in that manner.

The use of histology as a therapeutic endpoint also leads to several potential pitfalls. The first is in defining if the measurement of eosinophils is the most important (if not the only) correct histologic parameter to follow. Other pathologic features accompany esophageal eosinophilia, such as the elongation of rete pegs, basal zone hyperplasia, an increased number of mast cells, and dilation

of intercellular spaces⁴². It is unclear if all of these findings need to become normal in order to define a complete response. It also needs to be determined to what level eosinophils need to be reduced (or eliminated) to constitute a biologically meaningful response. Thus, in reading studies on EoE evaluating therapy, endpoints vary with different levels of eosinophil reduction including absolute numbers (e.g. <5) or percentage reduction. The main reason for this inability to establish a firm therapeutic histologic endpoint is the lack of knowledge of what is the natural history of EoE in the presence of these varied but sustained eosinophil levels. More specifically, we lack the knowledge of whether reduction to 15, 5 or 0 eosinophils per high power field prevents fibrosis and the progression of disease to strictures. Similarly, pathologists debate whether this measurement of eosinophils should be maximum or average per high power field and if all fields examined should be held to the same standard. With this in mind, the gold standard at this time remains elimination of all esophageal eosinophils, though, realistically, this is hard to achieve in all patients.

With these caveats in mind, medical treatment consists of pharmacologic and diet therapy. The first medication that should be considered in a patient with EoE is a PPI. Although one might define a response as indicating a patient with PPIREE, in a patient with classic features of EoE, I still consider this a first-line response. In patients with a typical phenotype of EoE, studies suggest a 30–60% initial response to PPI, but likely closer to 30%^{30,43}.

From a theoretical point of view, diet therapy for EoE appears most logical. This logic stems from the knowledge that food antigens trigger the T(H)2 allergic response and therefore preventing exposure to these foods putatively eliminates the disease. Unfortunately, determining specific foods that initiate this response in individual patients is difficult, owing to the lack of reliable non-invasive tests to identify culpable food antigens. In a recent meta-analysis, antigen determination in EoE through routine allergy testing in adults was only 45% accurate⁴⁴. As a result, endoscopy followed by biopsy remains the only test at this time that reliably evaluates the effects of foods on esophageal inflammation. This can lead to up to ten endoscopies required for individual patients to find these foods using a series of additions and withdrawals of potential dietary constituents followed by esophageal biopsies⁴⁵. Although newer methods of esophageal mucosa sampling are being developed, they are not ready for general use at this time. On the other hand, a recent meta-analysis of diet therapy demonstrated that six-food elimination and elemental diets led to remission in 75 and 95% of patients⁴⁴. Although the six-food elimination diet has appeared unattractive to patients given the commonality of the foods eliminated, variations of this diet are gaining more popularity. For example, preliminary work is being performed for four- and two-food elimination diets⁴⁶. Even so, as the population embraces current trends of avoiding gluten and dairy (the two most common food antigens that trigger EoE), elimination diets are becoming more acceptable to patients.

Although not a pharmacologic therapy, endoscopic dilation is an important part of therapy in EoE, particularly in adults where strictures are common. Early literature that evaluated dilation in patients with EoE suggested a high rate of perforation, warning against

its use or at least suggesting marked caution be taken⁴⁷. With the publication of far larger studies, a recent review suggests that the frequency of perforation is 1%, with most patients who sustain perforation responding to non-operative therapy⁴⁸. On the other hand, these studies demonstrate that dilation should be done gradually and carefully and perhaps over multiple sessions. With this in mind, dilation alone has been shown to be as effective in reducing symptoms of EoE as steroids in 2-year follow-up, although mechanical therapy directed at strictures does not improve histology⁴⁹. Rather than being viewed as an either/or therapy, in most adult patients therapeutic response is commonly achieved with a combination of medical and dilation therapy. This is particularly true in patients with marked esophageal narrowing, severe symptoms, or a history of food impaction.

One of the ongoing debates occurring in the field of EoE at present is the role of maintenance therapy. On the one hand, although EoE is not known to be associated with malignancy, there is concern that it leads to morbidity and chronic use of steroids. Furthermore, relapse is almost universal, there is a significant effect on quality of life, and severe complications such as food impaction or Boerhaave's syndrome^{49,50} may occur. Recent data also suggest that untreated inflammation eventually leads to stricture formation in most patients⁵⁰. As a result, physicians are starting to define subsets of patients who might benefit from maintenance therapy. These include patients with EoE who respond to PPIs, patients effectively managed with diet therapy, and those who have a rapid relapse of symptoms and/or eosinophilia, severe stricturing disease such as in small caliber esophagus, or a history of food impactions or perforation. Whether all patients will ultimately require maintenance therapy is unclear.

If it is decided that chronic pharmacologic maintenance therapy is needed, unfortunately it is not clear what dose of medication to use. For PPIs, there are no randomized studies examining their role in maintenance, let alone whether once- or twice-daily dosing is effective. For topical steroids, there is only one randomized trial demonstrating that 0.5 mg of budesonide daily is suboptimally effective⁵¹. At this point, anecdotal advice that varies from 1 mg every other day to 1 mg twice daily has been used to establish symptomatic and/or histologic remission.

Future directions

There are numerous areas that need to be elucidated further in the field of EoE, but several are more pressing than others. The first is to find a "gold standard" for the diagnosis of EoE. As discussed, consensus guidelines dictate that the diagnosis is made with use of compatible clinical, endoscopic, and histologic characteristics. Genetic testing, as discussed previously, may fulfill this role, although positive testing is not found in all patients. The second area is in developing a test that is less expensive and invasive than endoscopy to assess histologic activity. This is important for monitoring therapy. This is particularly true in patients undergoing diet therapy where it can take up to ten endoscopies to determine the specific foods to which the patient is allergic. Candidate devices include the esophageal string test⁵² and the cytosponge⁵³. Both are office-based procedures that do not require anesthesia. The hope for an easier test (such as through blood samples) is present, but results have not approached a level of accuracy amenable for practice. Finally, identification of subtypes of EoE, likely based on phenotype and/or genomic differences, will be helpful to define prognosis and predict the need for more intensive immediate and long-term therapy. Already, recent studies from the laboratories of Dr Marc Rothenberg (who has been pivotal in finding these genetic variations) have demonstrated an abnormal molecular profile in EoE patients which may also predict response to steroids^{54,55}.

Conclusion

EoE is a newly identified disease in which tremendous progress has been made in a matter of a couple of decades. From a classic description of an ostensibly rare disease, EoE is now a disease whose mechanism is well understood and has been well characterized, clinically, endoscopically, histologically, and genetically. Excellent and relatively safe treatment options are already available. Future clinical research on EoE is likely to concentrate mostly on the identification of a gold standard for diagnosis, the determination of factors that predict severe disease and response to treatment, and the role of maintenance therapy as we gain further understanding of the long-term complications of this disease.

Competing interests

The author declares that he has no competing interests.

References

- Sherrill JD, Rothenberg ME: **Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies.** *J Allergy Clin Immunol.* 2011; **128**(1): 23–32; quiz 33–4. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Lu TX, Sherrill JD, Wen T, et al.: **MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.** *J Allergy Clin Immunol.* 2012; **129**(4): 1064–75.e9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Rothenberg ME, Spergel JM, Sherrill JD, et al.: **Common variants at 5q22 associate with pediatric eosinophilic esophagitis.** *Nat Genet.* 2010; **42**(4): 289–91. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Blanchard C, Wang N, Stringer KF, et al.: **Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.** *J Clin Invest.* 2006; **116**(2): 536–47. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Sherrill JD, Gao PS, Stucke EM, et al.: **Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis.** *J Allergy Clin Immunol.* 2010; **126**(1): 160–5.e3. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Katzka DA, Tadi R, Smyrk TC, et al.: **Effects of topical steroids on tight junction proteins and spongiosis in esophageal epithelia of patients with eosinophilic esophagitis.** *Clin Gastroenterol Hepatol.* 2014; **12**(11): 1824–9.e1. [PubMed Abstract](#) | [Publisher Full Text](#)
- Blanchard C, Stucke EM, Burwinkel K, et al.: **Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis.** *J Immunol.* 2010; **184**(7): 4033–41. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kotlyan LC, Davis BP, Sherrill JD, et al.: **Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease.** *Nat Genet.* 2014; **46**(8): 895–900. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

9. **F** Rothenberg ME: **Biology and treatment of eosinophilic esophagitis.** *Gastroenterology*. 2009; **137**(4): 1238–49.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
10. Mishra A, Hogan SP, Brandt EB, *et al.*: **An etiological role for aeroallergens and eosinophils in experimental esophagitis.** *J Clin Invest*. 2001; **107**(1): 83–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Blanchard C, Wang N, Rothenberg ME: **Eosinophilic esophagitis: pathogenesis, genetics, and therapy.** *J Allergy Clin Immunol*. 2006; **118**(5): 1054–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Blanchard C, Rothenberg ME: **Basic pathogenesis of eosinophilic esophagitis.** *Gastrointest Endosc Clin N Am*. 2008; **18**(1): 133–43; x.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Abonia JP, Rothenberg ME: **Eosinophilic esophagitis: rapidly advancing insights.** *Annu Rev Med*. 2012; **63**: 421–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Roy-Ghanta S, Larosa DF, Katzka DA: **Atopic characteristics of adult patients with eosinophilic esophagitis.** *Clin Gastroenterol Hepatol*. 2008; **6**(5): 531–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Atkins D, Furuta GT: **Mucosal immunology, eosinophilic esophagitis, and other intestinal inflammatory diseases.** *J Allergy Clin Immunol*. 2010; **125**(2 Suppl 2): S255–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. **F** Schaefer ET, Fitzgerald JF, Molleston JP, *et al.*: **Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children.** *Clin Gastroenterol Hepatol*. 2008; **6**(2): 165–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
17. Lucendo AJ, De Rezende L, Comas C, *et al.*: **Treatment with topical steroids downregulates IL-5, eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in eosinophilic esophagitis.** *Am J Gastroenterol*. 2008; **103**(9): 2184–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. **F** Alexander JA, Jung KW, Arora AS, *et al.*: **Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis.** *Clin Gastroenterol Hepatol*. 2012; **10**(7): 742–749.e1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. Kelly KJ, Lazenby AJ, Rowe PC, *et al.*: **Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula.** *Gastroenterology*. 1995; **109**(5): 1503–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. **F** Peterson KA, Byrne KR, Vinson LA, *et al.*: **Elemental diet induces histologic response in adult eosinophilic esophagitis.** *Am J Gastroenterol*. 2013; **108**(5): 759–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
21. Wechsler JB, Schwartz S, Amsden K, *et al.*: **Elimination diets in the management of eosinophilic esophagitis.** *J Asthma Allergy*. 2014; **7**: 85–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Markowitz JE, Spergel JM, Ruchelli E, *et al.*: **Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents.** *Am J Gastroenterol*. 2003; **98**(4): 777–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. van Rhijn BD, Weijenborg PW, Verheij J, *et al.*: **Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis.** *Clin Gastroenterol Hepatol*. 2014; **12**(11): 1815–23.e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Aceves SS, Newbury RO, Dohil R, *et al.*: **Esophageal remodeling in pediatric eosinophilic esophagitis.** *J Allergy Clin Immunol*. 2007; **119**(1): 206–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Aceves SS, Newbury RO, Chen D, *et al.*: **Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids.** *Allergy*. 2010; **65**(1): 109–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. **F** Clayton F, Fang JC, Gleich GJ, *et al.*: **Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE.** *Gastroenterology*. 2014; **147**(3): 602–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
27. Alexander ES, Martin LJ, Collins MH, *et al.*: **Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis.** *J Allergy Clin Immunol*. 2014; **134**(5): 1084–1092.e1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Patel SM, Falchuk KR: **Three brothers with dysphagia caused by eosinophilic esophagitis.** *Gastrointest Endosc*. 2005; **61**(1): 165–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. **F** Liacouras CA, Furuta GT, Hirano I, *et al.*: **Eosinophilic esophagitis: updated consensus recommendations for children and adults.** *J Allergy Clin Immunol*. 2011; **128**(1): 3–20.e6; quiz 21–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
30. **F** Dellon ES, Gonsalves N, Hirano I, *et al.*: **ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE).** *Am J Gastroenterol*. 2013; **108**(5): 679–92; quiz 693.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. **F** Kapel RC, Miller JK, Torres C, *et al.*: **Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups.** *Gastroenterology*. 2008; **134**(5): 1316–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
32. Markowitz JE, Liacouras CA: **Ten years of eosinophilic esophagitis: small steps or giant leaps?** *Dig Liver Dis*. 2006; **38**(4): 251–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Spechler SJ, Genta RM, Souza RF: **Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis.** *Am J Gastroenterol*. 2007; **102**(6): 1301–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Francis DL, Foxx-Orenstein A, Arora AS, *et al.*: **Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic esophagitis.** *Aliment Pharmacol Ther*. 2012; **35**(2): 300–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Sridhara S, Ravi K, Smyrk TC, *et al.*: **Increased numbers of eosinophils, rather than only etiology, predict histologic changes in patients with esophageal eosinophilia.** *Clin Gastroenterol Hepatol*. 2012; **10**(7): 735–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Dellon ES, Speck O, Woodward K, *et al.*: **Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study.** *Clin Gastroenterol Hepatol*. 2014; **12**(12): 2015–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Zhang X, Cheng E, Huo X, *et al.*: **Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells.** *PLoS One*. 2012; **7**(11): e50037.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Cheng E, Zhang X, Huo X, *et al.*: **Omeprazole blocks eotaxin-3 expression by esophageal squamous cells from patients with eosinophilic esophagitis and GORD.** *Gut*. 2013; **62**(6): 824–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Alexander J, Katzka D: **Editorial: expanding a narrow perspective on narrow calibre esophagus in eosinophilic esophagitis—authors' reply.** *Aliment Pharmacol Ther*. 2015; **41**(1): 148–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Dellon ES, Gibbs WB, Fritchie KJ, *et al.*: **Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease.** *Clin Gastroenterol Hepatol*. 2009; **7**(12): 1305–13; quiz 1261.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Schoefer A, Safroneeva E: **Activity assessment of eosinophilic esophagitis.** *Dig Dis*. 2014; **32**(1–2): 98–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Odze RD: **Histologic features of gastroesophageal reflux disease and eosinophilic esophagitis.** *Gastroenterol Hepatol (N Y)*. 2012; **8**(7): 472–3.
[PubMed Abstract](#) | [Free Full Text](#)
43. **F** Molina-Infante J, Ferrando-Lamana L, Ripoll C, *et al.*: **Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.** *Clin Gastroenterol Hepatol*. 2011; **9**(2): 110–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Arias A, González-Cervera J, Tenias JM, *et al.*: **Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis.** *Gastroenterology*. 2014; **146**(7): 1639–48.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. **F** Lucendo AJ, Arias A, González-Cervera J, *et al.*: **Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease.** *J Allergy Clin Immunol*. 2013; **131**(3): 797–804.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. **F** Molina-Infante J, Arias A, Barrio J, *et al.*: **Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study.** *J Allergy Clin Immunol*. 2014; **134**(5): 1093–9.e1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. Cohen MS, Kaufman AB, Palazzo JP, *et al.*: **An audit of endoscopic complications in adult eosinophilic esophagitis.** *Clin Gastroenterol Hepatol*. 2007; **5**(10): 1149–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Moawad FJ, Cheatham JG, DeZee KJ: **Meta-analysis: the safety and efficacy of dilation in eosinophilic esophagitis.** *Aliment Pharmacol Ther*. 2013; **38**(7): 713–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Lipka S, Keshishian J, Boyce HW, *et al.*: **The natural history of steroid-naïve eosinophilic esophagitis in adults treated with endoscopic dilation and proton pump inhibitor therapy over a mean duration of nearly 14 years.** *Gastrointest Endosc*. 2014; **80**(4): 592–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. **F** Schoefer AM, Safroneeva E, Bussmann C, *et al.*: **Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.** *Gastroenterology*. 2013; **145**(6): 1230–6.e1–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

51. **F** Straumann A, Conus S, Degen L, *et al.*: **Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.** *Clin Gastroenterol Hepatol.* 2011; **9**(5): 400–9.e1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
52. **F** Furuta GT, Kagalwalla AF, Lee JJ, *et al.*: **The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis.** *Gut.* 2013; **62**(10): 1395–405.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. Katzka DA, Geno DM, Ravi A, *et al.*: **Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis.** *Clin Gastroenterol Hepatol.* 2015; **13**(1): 77–83.e2.
[PubMed Abstract](#) | [Publisher Full Text](#)
54. **F** Wen T, Stucke EM, Grotjan TM, *et al.*: **Molecular diagnosis of eosinophilic esophagitis by gene expression profiling.** *Gastroenterology.* 2013; **145**(6): 1289–99.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
55. Wen T, Dellon ES, Moawad FJ, *et al.*: **Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation.** *J Allergy Clin Immunol.* 2015; **135**(1): 187–197.e4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 20 August 2015

<https://doi.org/10.5256/f1000research.7475.r10034>

© 2015 Markowitz J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jonathan Markowitz

Pediatric Gastroenterology, Greenville Hospital System University Medical Center, Greenville, SC, USA

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 20 August 2015

<https://doi.org/10.5256/f1000research.7475.r10033>

© 2015 Rothenberg M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Marc Rothenberg

Cincinnati Children's Hospital Medical Center, Cincinnati OH, USA

No further comments provided.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 20 August 2015

<https://doi.org/10.5256/f1000research.7475.r10032>

© 2015 Liacouras C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chris Liacouras

Division of Gastroenterology, The Children's Hospital of Philadelphia, Philadelphia, PA, UK

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research